SCHEMBL948655

SCHEMBL948655

CC(C)(C)OC(=O)N1CCC(NC(=O)c2cnc3n2CCCC3)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
USP30 Q70CQ3 3/20 0.48
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
POLB P06746 2/20 0.46
LMNA P02545 2/20 0.45
HDAC4 P56524 1/20 0.44
THRB P10828 1/20 0.44
ALPL P05186 1/20 0.44
ALPI P09923 1/20 0.44
ALPG P10696 1/20 0.44
GAA P10253 1/20 0.44
PARP1 P09874 1/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL948718 0.79 HPGD (0.48) MEN1KMT2APOLBTHRBHPGD
SCHEMBL949278 0.74 USP30 (0.54) EPHX1L3MBTL1USP30ALDH1A1MEN1
SCHEMBL23107983 0.74 USP30 (0.64) EPHX1L3MBTL1USP30ALDH1A1MEN1
SCHEMBL1994032 0.73 HDAC4 (0.56) EPHX1L3MBTL1USP30ALDH1A1MEN1
SCHEMBL2957946 0.73 EPHX1 (0.55) EPHX1L3MBTL1USP30ALDH1A1MEN1
SCHEMBL12124466 0.73 EPHX1 (0.52) EPHX1L3MBTL1USP30ALDH1A1MEN1
SCHEMBL16984667 0.72 USP30 (0.57) EPHX1L3MBTL1USP30ALDH1A1MEN1
SCHEMBL21171966 0.72 EPHX1 (0.51) EPHX1L3MBTL1USP30ALDH1A1MEN1
SCHEMBL17592125 0.71 L3MBTL1 (0.60) EPHX1L3MBTL1USP30ALDH1A1MEN1
SCHEMBL2954898 0.71 HDAC4 (0.56) EPHX1L3MBTL1USP30ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 EPHX1 789/4885L3MBTL1 2949/4885USP30 3776/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 EPHX1 894/4885L3MBTL1 2955/4885USP30 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.